ĐÁNH GIÁ KẾT QUẢ BAN ĐẦU SỬ DỤNG LUCENTIS TIÊM NỘI NHÃN ĐIỀU TRỊ THOÁI HÓA HOÀNG ĐIỂM TUỔI GIÀ THỂ TÂN MẠCH TẠI BỆNH VIỆN HỮU NGHỊ

Abstract

Objective: Evaluation of initial results using Lucentis intraocular injection to treat Wet Aged-related macular at Huu Nghi hospital. Medthodology: An uncontrolled intervention study was conducted on 40 eyes with Wet Aged-related macular at the Department of Ophthalmology, Huu Nghi Hospital from January 2018 to May 2021. All patients received 3 consecutive intravitreal injections of Lucentis 1 month apart and were followed up monthly for anatomical and functional outcomes. Results: The average age is 78.88; 72.5% were male, the patient came mainly with blurred vision (100%), the patient's pre-treatment vision was very poor. The average central retinal thickness was 300.06 ± 48.05 μm, the average number of injections was 3.4 injections; 90% of patients only need 3 injections to stabilize and maintain good vision. The mean central retinal thickness decreased by approximately 52.67 μm (from 300.06 μm to 247.92 μm) during the study period. At the end of follow-up, the central retinal thickness had returned to almost normal and the difference was statistically significant compared to before treatment (p<0.05). Average visual acuity increased by 4.75 words after treatment, 7.5% of eyes had good visual acuity improvement, no eyes had decreased vision. Conclusion: Intraocular Lucentis injection for the treatment of Wet Aged-related macular is a safe, low-risk and effective treatment method.